Overview

* Recursion Q3 operating revenue misses analyst expectations

* Net loss for Q3 widens, missing analyst estimates

* Achieved $30 mln milestone from Roche and Genentech for microglial immune cells map

Outlook

* Recursion expects cash runway to extend through 2027 without additional financing

* Company anticipates over $100 mln in milestone payments by end of 2026

Result Drivers

* MILESTONE PAYMENT - Achieved $30 mln milestone from Roche and Genentech for microglial immune cells map

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $4.98 $17 mln

Operatin mln (6

g Analysts

Revenue )

Q3 Net Miss -$162.25 -$146.90

Income mln mln (3

Analysts

)

Q3 Miss -$162.25 -$128.90

Pretax mln mln (1

Profit Analyst)

Q3 -$172.20

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc ( RXRX ) is $6.50, about 23.1% above its November 4 closing price of $5.00

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)